Know Cancer

forgot password

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

18 Years
Open (Enrolling)
Retinal Hemangioma

Thank you

Trial Information

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

The treatment plan will be to administer aflibercept 2.0 mg intravitreally every two to four
weeks for at least six consecutive injections. Prior to initiation of therapy and at each
study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete
review of systems to monitor for any toxicity will be performed. In addition, the
investigators will perform fluorescein and indocyanine green angiography at baseline and
obtain color fundus photographs as well as spectral domain OCT images to properly document
the extent and degree of activity of the vascular tumor at baseline and at all study visits.

Inclusion Criteria:

- retinal hemangioma

- previously treated with conventional therapies, including Avastin, Lucentis, steroid,
and photodynamic therapy, with less than ideal results

Exclusion Criteria:

- ongoing reevaluation of adverse events, including inflammation, elevated intraocular
pressure, or any suspected toxicity from aflibercept

Type of Study:

Expanded Access

Study Design:



United States: Food and Drug Administration

Study ID:

Slakter 1234



Start Date:

Completion Date:

Related Keywords:

  • Retinal Hemangioma
  • Hemangioma
  • Eye Neoplasms
  • Retinal Diseases



Vitreous Retina Macula Consultants of New York New York, New York  10022